Biology Reference
In-Depth Information
Chapter 5
Siderophore-Mediated Iron Acquisition:
Target for the Development of Selective
Antibiotics Towards
Mycobacterium
tuberculosis
Raúl E. Juárez-Hernández, Helen Zhu and Marvin J. Miller
Abstract
This chapter reviews recent pertinent literature on the
Mycobacterium
tuberculosis
siderophore mycobactin and its excreted counterpart carboxymy-
cobactin. Emphasis is placed on the design of antibiotics to specifically interfere
with the biosynthesis of these siderophores and the use of siderophore analogs
or conjugates to achieve inhibition of
M
.
tuberculosis
. Although the discussion is
focused on biological activity of potential anti-tuberculosis agents, a brief descrip-
tion of the synthetic routes for compounds of interest is given.
Keywords
Mycobacterium tuberculosis
• TB • Mycobactins • Siderophore •
Siderophore-antibiotic conjugates • Antibiotics • Sideromycins • MDR (multi-drug
resistant) • XDR (extensively-drug resistant) • Biosynthesis inhibitors
5.1 Introduction
Approximately one out of every three people living on this planet is infected with
M
.
tuberculosis,
the causative agent of the contagious disease tuberculosis (TB). It
is estimated that in 2009, close to 1.7 million of people died because of this infec-
tion [
1
]. Similar to the emergence of other antibiotic-resistant bacteria, the diagno-
sis of multi-drug resistant (MDR) and extensively-drug resistant (XDR) strains of
M. tuberculosis
[
2
] has sparked interest around the world to develop new agents
that can be used to eradicate disease caused by this deadly microorganism [
3
-
11
].
R. E. Juárez-Hernández (
*
) · H. Zhu · M. J. Miller
Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN,
USA
e-mail: rxj159@case.edu
M. J. Miller
e-mail: mmiller1@nd.edu
Search WWH ::
Custom Search